An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab

ClinicalTrials.gov ID: NCT07832136

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07832136. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4, Single-Arm, Open-Label Trial to Evaluate the Safety and Efficacy of Veligrotug in Participants With Thyroid Eye Disease (TED) Who Previously Responded to Teprotumumab

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but subsequently had a disease recurrence.

Study identification

NCT ID: NCT07832136
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Thyroid Eye Disease

Interventions

veligrotrug (LUMVOA™) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2026 (Estimated)
Primary completion: Apr 2027 (Estimated)
Completion: Sep 2027 (Estimated)
Last update posted: Sep 21, 2026

2026 – 2027

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Office of Dr. Amy Patel Jain, MD	Newport Beach	California	92660	—
Sarasota Retina Institute	Sarasota	Florida	34239	—
Ophthalmic Consultants of Boston	East Weymouth	Massachusetts	02189	—
Kahana Oculoplastic & Orbital Surgery	Livonia	Michigan	48152	—
University Health	Kansas City	Missouri	64108	—
The Center for Eye and Facial Plastic Surgery	Somerset	New Jersey	08873	—
Neuro-Eye Clinical Trials	Houston	Texas	34239	—
Baylor College of Medicine Alkek Eye Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07832136, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 21, 2026 · Synced Nov 15, 2026